86 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
of early clinical activity for a CDK2 inhibitor in combination with an approved CDK4/6 inhibitor at the 2024 American Society of Clinical Oncology (ASCO
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
at the 2023 American Society of Hematology annual meeting. Read the presentations here.
Breast cancer and other solid tumors
Advanced the development of BLU
8-K
EX-99.1
dgpxrp5b
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.1
vbrfvlez8gzdyq12lt9f
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
47tlfnu5ia 8ltha
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
EX-99.1
fy1f02r6pd9sp3k
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am
8-K
EX-99.2
4pp2xs7ylu
1 Nov 22
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale
8:08am
8-K
EX-99.1
pk74h4zyvhdtvs9mpz
17 Aug 22
Other Events
7:28am
8-K
EX-99.1
opivqdy badj5na
10 Jan 22
Regulation FD Disclosure
8:27am